Biotech · Public company · Somerville, MA, US

Generate Biomedicines, Inc.

Ticker GENB · SEC CIK 0002100782

Track this companyFree. Adds Generate Biomedicines, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials65 recruiting or active

Pipeline programs6From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline6

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube CancerPHASE1 · RECRUITING · started Aug 18, 2026ClinicalTrials.gov NCT07489287 · fetched Nov 12, 2026
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerPHASE1 · RECRUITING · started Jun 8, 2026ClinicalTrials.gov NCT07484022 · fetched Nov 12, 2026
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)PHASE3 · RECRUITING · started Jan 20, 2026ClinicalTrials.gov NCT07359846 · fetched Nov 12, 2026
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)PHASE3 · RECRUITING · started Dec 3, 2025ClinicalTrials.gov NCT07276724 · fetched Nov 12, 2026
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPDPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 12, 2023ClinicalTrials.gov NCT07116889 · fetched Nov 12, 2026
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-0669 in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Jul 18, 2023ClinicalTrials.gov NCT07050511 · fetched Nov 12, 2026